Orna Therapeutics Acquires ReNAgade for Circular RNA Therapies
Shots:
- Under the acquisition, Orna will combine its circular RNA technology with ReNAgade’s LNP-based RNA delivery systems and comprehensive editing programs
- Acquistion will advance panCAR in vivo CAR RNA medicines for oncology and autoimmune diseases, vaccines in Merck’s partnership, and genetic disease programs
- Following acquisition, Orna Therapeutics and ReNAgade will bring substantial finance, as Orna raised $100M & $221M from Series A & Series B in Feb 2021 and Aug 2022, respectively, whereas ReNAgade raised $300M from Series A in May 2023
Ref: Orna Therapeutics | Image: Orna Therapeutics
Related News: Merck Collaborated with Orna Therapeutics to Advance RNA Therapies for Infectious Disease and Oncology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
